{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:52:35Z","timestamp":1740181955739,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Squamous cell carcinoma of the esophagus ranks as the most common cause of cancer incidence and mortality in males and the second most common in females. Surgery alone is associated with poor long-term survival. Neoadjuvant chemoradiation and perioperative chemotherapy without radiation have been tried to improve survival rates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively evaluated the neoadjuvant chemotherapy in forty-eight patients with non-metastatic, non-cervical squamous cell carcinoma of the esophagus with a docetaxel-based three-drug regimen to improve complete pathological response rates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median age of presentation was 52 years, with male preponderance. All the patients received three cycles of docetaxel-cisplatin-fluorouracil-based chemotherapy. A complete pathological response to neoadjuvant chemotherapy was seen in 8 patients (17%). Rates of grade 3 hematological toxicities were seen in 12% of patients, with no observed grade 4 toxicity. The most common non-hematological toxicity was grade 3 alopecia (seen in 40%) and grade 2 nausea\/vomiting in 8% of patients. At a median follow-up of 26.5 months, 2-year survival for the patients receiving chemotherapy and surgery is 66%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Preoperative chemotherapy with a taxane-based triple-drug regimen is a reasonable approach in squamous cell carcinoma of the esophagus, associated with improvement in complete pathological response rates, increases complete resection rates, with manageable toxicity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43046-021-00094-0","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T13:03:48Z","timestamp":1634821428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinico-epidemiological profile and treatment outcomes in patients with squamous cell carcinoma of the esophagus following docetaxel-based neoadjuvant chemotherapy: experience from a cancer care center in Northeast India"],"prefix":"10.1186","volume":"33","author":[{"given":"Partha Sarathi","family":"Roy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7383-7413","authenticated-orcid":false,"given":"Gaurav","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreya","family":"Mallik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satya Sadhan","family":"Sarangi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhargab Jyoti","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munlima","family":"Hazarika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijit","family":"Talukdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"94_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"94_CR2","doi-asserted-by":"publisher","first-page":"600","DOI":"10.4103\/0019-509X.204764","volume":"53","author":"JD Sharma","year":"2016","unstructured":"Sharma JD, Kataki AC, Barman D, Sharma A, Kalita M. Cancer statistics in Kamrup urban district: incidence and mortality in 2007\u20132011. Indian J Cancer. 2016;53:600\u20136.","journal-title":"Indian J Cancer"},{"key":"94_CR3","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1056\/NEJM199812313392704","volume":"339","author":"DP Kelsen","year":"1998","unstructured":"Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979.","journal-title":"N Engl J Med"},{"key":"94_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJM199707173370304","volume":"337","author":"JF Bosset","year":"1997","unstructured":"Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161.","journal-title":"N Engl J Med"},{"key":"94_CR5","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1056\/NEJMoa022343","volume":"347","author":"JB Hulscher","year":"2002","unstructured":"Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited trans-hiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662.","journal-title":"N Engl J Med"},{"key":"94_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/00000658-200208000-00005","volume":"236","author":"N Altorki","year":"2002","unstructured":"Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg. 2002;236:177.","journal-title":"Ann Surg"},{"key":"94_CR7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/00000658-199909000-00012","volume":"230","author":"MB Orringer","year":"1999","unstructured":"Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg. 1999;230:392.","journal-title":"Ann Surg"},{"key":"94_CR8","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1200\/JCO.2007.12.9593","volume":"26","author":"J Tepper","year":"2008","unstructured":"Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodal therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086\u201392.","journal-title":"J Clin Oncol"},{"key":"94_CR9","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074\u201384.","journal-title":"N Engl J Med"},{"key":"94_CR10","doi-asserted-by":"crossref","unstructured":"Ando N, Kato H, Igaki Het al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68\u201374.","DOI":"10.1245\/s10434-011-2049-9"},{"key":"94_CR11","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa071028","volume":"357","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695\u2013704.","journal-title":"N Engl J Med"},{"key":"94_CR12","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa070956","volume":"357","author":"MR Posner","year":"2007","unstructured":"Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705\u201315.","journal-title":"N Engl J Med"},{"key":"94_CR13","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991\u20137.","journal-title":"J Clin Oncol"},{"key":"94_CR14","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ijc.31312","volume":"143","author":"KKW Chan","year":"2018","unstructured":"Chan KKW, Saluja R, Delos Santos K, et al. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: a network meta-analysis. Int J Cancer. 2018;143:430.","journal-title":"Int J Cancer"},{"issue":"11","key":"94_CR15","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1002\/1097-0142(20010601)91:11<2165::AID-CNCR1245>3.0.CO;2-H","volume":"91","author":"E Ancona","year":"2001","unstructured":"Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: trial report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001;91(11):2165\u201374.","journal-title":"Cancer."},{"issue":"2","key":"94_CR16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0022-5223(19)35265-1","volume":"96","author":"JA Roth","year":"1988","unstructured":"Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S, et al. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma esophagus. J Thorac Cardiovasc Surg. 1988 Aug;96(2):242\u20138.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"11","key":"94_CR17","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/cas.12274","volume":"104","author":"H Hara","year":"2013","unstructured":"Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, et al. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci. 2013;104(11):1455\u201360. https:\/\/doi.org\/10.1111\/cas.12274 Epub 2013 Oct 18. PMID: 23991649.","journal-title":"Cancer Sci"},{"issue":"4","key":"94_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4103\/0970-0218.164399","volume":"40","author":"A Kapoor","year":"2015","unstructured":"Kapoor A, Kumar V, Singhal MK, Nirban RK, Beniwal SK, Kumar HS, et al. Socio-demographic parameters of esophageal cancer in Northwest India: a regional cancer center experience of 10 years. Indian J Community Med. 2015;40(4):264\u20137. https:\/\/doi.org\/10.4103\/0970-0218.164399.","journal-title":"Indian J Community Med"},{"key":"94_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4103\/0019-509X.102921","volume":"49","author":"S Sehgal","year":"2012","unstructured":"Sehgal S, Kaul S, Gupta BB, Dhar MK. Risk factors and survival analysis of esophageal cancer in the population of Jammu, India. Indian J Cancer. 2012;49:245\u201350.","journal-title":"Indian J Cancer"},{"issue":"9","key":"94_CR20","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomized controlled trial. Lancet Oncol. 2015;16(9):1090 Epub 2015 Aug 5.","journal-title":"Lancet Oncol"},{"key":"94_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/1477-7819-11-257","volume":"11","author":"MD Mchembe","year":"2013","unstructured":"Mchembe MD, Rambau PF, Chalya PL, et al. Endoscopic and clinic-pathological patterns of esophageal cancer in Tanzania: experiences from two tertiary health institutions. World J Surg Oncol. 2013;11:257.","journal-title":"World J Surg Oncol"},{"key":"94_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/1471-2407-11-181","volume":"11","author":"JJ Boonstra","year":"2011","unstructured":"Boonstra JJ, Kok TC, Wijnhoven BP, van Heijl M, van Berge Henegouwen MI, Ten Kate FJ, et al. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer. 2011;11:181.","journal-title":"BMC Cancer"},{"key":"94_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Cornelis JH, de Velde V, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med"},{"issue":"4","key":"94_CR24","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/annonc\/mdw010","volume":"27","author":"F Klevebro","year":"2016","unstructured":"Klevebro F, von D\u00f6beln GA, Wang N, Johnsen G, Jacobsen AB, Friesland S, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastro-oesophageal junction. Ann Oncol. 2016;27(4):660\u20137 Epub 2016 Jan 17.","journal-title":"Ann Oncol"},{"issue":"9319","key":"94_CR25","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/S0140-6736(02)08651-8","volume":"359","author":"Medical Research Council Oesophageal Cancer Working Group","year":"2002","unstructured":"Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet. 2002;359(9319):1727.","journal-title":"Lancet"},{"key":"94_CR26","doi-asserted-by":"publisher","first-page":"272","DOI":"10.4103\/ijmpo.ijmpo_16_16","volume":"39","author":"HK Bajwa","year":"2018","unstructured":"Bajwa HK, Singareddy R, Reddy MM, Raju KA, Rao ST, Rajappa SJ. Preoperative chemoradiation in carcinoma esophagus: experience from a tertiary cancer center in India. Indian J Med Paediatr Oncol. 2018;39:272\u20135.","journal-title":"Indian J Med Paediatr Oncol"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-021-00094-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-021-00094-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-021-00094-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T13:08:12Z","timestamp":1634821692000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-021-00094-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["94"],"URL":"https:\/\/doi.org\/10.1186\/s43046-021-00094-0","relation":{},"ISSN":["2589-0409"],"issn-type":[{"type":"electronic","value":"2589-0409"}],"subject":[],"published":{"date-parts":[[2021,10,21]]},"assertion":[{"value":"13 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional ethics committee (BBCI Medical Ethics committee; Ref No.: BBCI-TMC\/Misc-01\/MEC\/53\/2019) approval was obtained for the study before reviewing the patient records and the study conformed to the Declaration of Helsinki. Written individual consent to participate in this study is not required as it is a retrospective and an observational study and participants were not subjected to any of the under trial or new drugs or treatment modalities. All participants included in this study received standard of care treatment as per various national and international guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written individual consent for publication of this study is not required as it is a retrospective and an observational study and participants were not subjected to any of the under trial or new drugs or treatment modalities. This study does not provide any information on public platform which reveals the identity of its participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}